Published in Gene Therapy Weekly, June 14th, 1999
The new findings help clarify why ARF is the second most frequently mutated gene in human cancers, appearing in 40 percent of malignancies, second only to the mutated tumor suppressor gene, p53.
According to a report in the journal Molecular Cell, published May 20, 1999, ARF normally prevents cellular transformation by preventing degradation of the p53 protein. It allows p53 to accumulate in the cell's nucleus where it functions to stop tumor cell growth.
...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (1999-06-14)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.